Please provide your email address to receive an email when new articles are posted on . Adults receiving tirzepatide had greater improvement in PHQ-9 score than those receiving placebo. Suicidal ...
Once-weekly subcutaneous tirzepatide administered for 72 weeks was not associated with an increased risk for depression compared with placebo in adults with overweight or obesity, with or without type ...
Independent analysis of several thousand clinical surveys confirms statistically significant, durable improvement across ...
New data from LifeStance Health indicates that most patients in its 2024–2025 cohort experienced significant improvement in depression and anxiety symptoms. Using PHQ-9 and GAD-7 assessments, 73% of ...
Via AllOne Health, the Employee Assistance Program (EAP) provider for Purdue’s West Lafayette campus, employees have access to a variety of assessments, including a depression screening survey. The ...
The Patient Health Questionnaire-9 (PHQ-9) is a tool most clinicians are familiar with. It's quick, familiar, and widely trusted across health care settings. However, when a patient's results indicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results